4'-chlorodiazepam--agonist of peripheral benzodiazepine receptors as a protecting factor in IL-1 induced deregulation of collagen biosynthesis in cultured human chondrocytes.
Degenerative joint diseases are related to the excessive degradation of collagen and proteoglycans in cartilage. One of the potent inflammatory mediators of cartilage metabolism is interleukin-1 (IL-1) that has been implicated in the pathogenesis of degenerative joint diseases. Peripheral benzodiazepine receptor ligands have anti-inflammatory activity in rheumatoid arthritis. The present study shows that 4'-chlorodiazepam (Ro-54864), an agonist of peripheral benzodiazepine receptors, counteract inhibition of collagen and DNA biosynthesis, induced by IL-1. Pk-1195, an antagonist of peripheral benzodiazepine receptors did not restore inhibitory effects of IL-1. The mechanism of collagen biosynthesis and cell division regulation involves insulin-like growth factor-I receptor signaling. We found that IL-1 inhibited expression of IGF-IR, while Ro-54864 stimulated the expression of this receptor. Increase in the expression of this receptor was accompanied by increase in mTOR expression and AKT phosphorylation while it had no effect on Ras-Raf-mitogen activated protein kinase (MAPK) pathway. Although IL-1 caused activation of apoptosis in chondrocytes, an addition of Ro-54864 to the cells inhibited the process as detected by annexin V cell staining followed by flow cytometry. The mechanism of this process may be related to protective effect of signal induced by IGF-I receptor. The data suggest that the mechanism of the protective effects of Ro-54864 on IL-1-induced effects in chondrocytes undergoes through mTOR and AKT signaling. It suggest that peripheral benzodiazepine receptor agonist may be considered as a potential pharmacotherapeutical agents in the treatment of inflammatory diseases.
Miltyk
Wojciech
W
Department of Pharmaceutical Analysis, Medical University in Bialystok, Bialystok, Poland.
Surazynski
Arkadiusz
A
Dondziło
Joanna
J
Palka
Jerzy
J
D017209:Apoptosis / Q000187:drug effects; D001570:Benzodiazepinones / Q000494:pharmacology*; D002356:Cartilage / Q000378:metabolism; D002478:Cells, Cultured; D019902:Chondrocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000096:biosynthesis; D003292:Convulsants / Q000494:pharmacology*; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000494:pharmacology; D007375:Interleukin-1 / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology*; D007546:Isoquinolines / Q000378:metabolism / Q000494:pharmacology; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism / Q000494:pharmacology; D010003:Osteoarthritis / Q000188:drug therapy / Q000503:physiopathology; D020011:Protective Agents / Q000378:metabolism / Q000494:pharmacology*; D011509:Proteoglycans / Q000378:metabolism / Q000494:pharmacology; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D011963:Receptors, GABA-A / Q000378:metabolism* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects
D001570:Benzodiazepinones; D003292:Convulsants; D007375:Interleukin-1; D007546:Isoquinolines; D020011:Protective Agents; D011509:Proteoglycans; D011963:Receptors, GABA-A; C028513:4'-chlorodiazepam; D007334:Insulin-Like Growth Factor I; D003094:Collagen; D017526:Receptor, IGF Type 1; D020928:Mitogen-Activated Protein Kinases; C037850:PK 11195